Lataa...
Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
Erlotinib, an epidermal growth factor receptor and tyrosine kinase inhibitor, is a targeted drug that was approved for the treatment of non-small-cell lung cancers and pancreatic cancers. Targeted tyrosine kinase inhibitors are known to have cardiotoxic effects. However, erlotinib does not have a st...
Tallennettuna:
| Julkaisussa: | Onco Targets Ther |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485179/ https://ncbi.nlm.nih.gov/pubmed/26150726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84480 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|